Pfizer Inc. (PFE)

NYSE: PFE · USD

$25.8

+0.40 (+1.6%)· Recorded snapshot

Coverage state: Latest published research available

Market snapshot recorded 2026-08-06 02:00 UTC. Latest published research analyzed 2026-05-09 · stale · sources unverified. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate a fresh PFE analysis

The published report stays available while a new owner-requested analysis runs.

StockMarketAgent Research · Analyzed 2026-05-09

Our latest published analysis: PFE rated Buy

Buy. Extreme pessimism creates a 17.76% margin of safety to our $30.24 fair value, provided management secures the dividend through the LOE trough.

Fair value (mid)

$30.2 / share

$25.1 – $35.4

Upside to FV

+17.8%

from $25.8

Confidence

86/100

Moat

6.5/10

Read full analysis

Market cap	$146.4B
Revenue (ttm)	63.7B
Net income (ttm)	4.3B
EPS (ttm)	$0.76
Shares out	5.7B
P/E (trailing)	33.9x
P/E (forward)	9.0x
Dividend	$1.72 (6.66%)
Volume	47,084,187
Beta	0.28
Price target	$29.0	+12.3%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 63.7B
Net income (ttm): 4.3B
EPS (ttm): $0.76
P/E (trailing): 33.9x
P/E (forward): 9.0x
Market cap: $146.4B

Item	P1	P2	P3	P4	P5	Trend
Period	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31	Trend
Revenue	$81.29B	$101.18B	$59.55B	$63.63B	$62.58B	-6.3%
Gross profit	$50.47B	$66.83B	$34.60B	$45.78B	$46.51B	-2.0%
Operating income	$20.24B	$37.16B	$4.22B	$14.83B	$15.79B	-6.0%
Net income	$21.98B	$31.37B	$2.12B	$8.03B	$7.77B	-22.9%
EPS (diluted)	$3.85	$5.47	$0.37	$1.41	$1.36	-22.9%
EBITDA	$30.79B	$41.03B	$9.56B	$18.13B	$16.78B	-14.1%
R&D	$13.83B	$12.38B	$10.87B	$10.93B	$12.05B	-3.4%
SG&A	$12.70B	$13.68B	$14.77B	$14.73B	$13.79B	+2.1%

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ABBV	AbbVie Inc.	430.9B	69.6x	6.7x	17.7%	+3.7%	+26.6%	Hold
ABT	Abbott Laboratories	186.8B	34.9x	4.0x	7.5%	+3.0%	-15.5%	Strong Buy
ACN	Accenture plc	104.7B	13.7x	1.4x	27.1%	+8.8%	-28.4%	Buy
AMGN	Amgen Inc.	218.9B	25.2x	5.7x	19.8%	+8.4%	+39.0%	Strong Buy
BIIB	Biogen Inc.	30.5B	36.6x	3.0x	8.9%	-3.0%	+55.2%	Strong Buy
BMY	Bristol-Myers Squibb Company	131B	14.1x	2.7x	21.7%	+2.1%	+46.6%	Strong Buy

All PFE indicators

Market & fundamental data

Available fields

286

Groups with data

Currency

USD

Showing 286 of 286 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0000078003
Company name	Pfizer Inc.
Country	United States
Country code	US
Cusip	717081103
Employees	75,000
Employees Change	-6,000%
Employees Change Percent	-7.41
Enterprise value	$198.9B
Exchange	NYSE
Financial currency	USD
First seen	2026-05-09
In Index	SP500
Industry	Drug Manufacturers - General
Industry PE	31.52
Industry PE Fwd	17.48
Isin	US7170811035
Last refreshed	2026-08-06
Market cap	$147.1B
Market cap category	Large-Cap
Price	$25.81
Price currency	USD
Rev Per Employee	849,280x
Sector	Healthcare
Sector PE	48.37
Sector PE Fwd	22.54
Sic	2834
Symbol	PFE
Tags	weight-loss
Website	https://www.pfizer.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	2.95%
EV Earnings	45.89x
EV Sales Forward	3.26x
EV/EBIT	47.25x
EV/EBITDA	18.43x
EV/FCF	18.11x
EV/Sales	3.12x
FCF yield	7.47%
Forward P/E	9.28x
P/B ratio	1.73x
P/E ratio	33.93x
P/S ratio	2.31x
PE Ratio10 Y	18.97x
PE Ratio3 Y	26.74x
PE Ratio5 Y	19.53x
PS Forward	2.41x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	6.61%
EBITDA Margin	16.94%
FCF margin	17.25%
Gross margin	74.72%
Gross Profit	$47.6B
Gross Profit Growth	2.68%
Gross Profit Growth Q	2.04%
Gross Profit Growth3 Y	-4.76%
Gross Profit Growth5 Y	3.85%
Net Income	$4.3B
Net Income Growth	-59.69%
Net Income Growth Years	0%
Net Income Growth3 Y	-41.34%
Net Income Growth5 Y	-19.42%
Pretax Margin	6.61%
Profit Margin	6.8%
Profit Per Employee	$57,787
Profitable Quarters	$1
Profitable Years	35
ROA	5.78
Roa5y	7.03
ROCE	2.5
ROE	5.01
Roe5y	17.68
ROIC	13.49
Roic5y	18.62

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	2.02%
Cagr15y	7.47%
Cagr1y	17.4%
Cagr20y	4.76%
Cagr3y	-3.67%
Cagr5y	-5.74%
Div CAGR10	3.84%
Div CAGR3	1.81%
Div CAGR5	2.1%
EPS Growth	-59.88
EPS Growth Years	0
EPS Growth3 Y	-41.3
EPS Growth5 Y	-19.56
FCF Growth	-11.68%
FCF Growth3 Y	0.99%
FCF Growth5 Y	-12.27%
OCF Growth	-11.77%
OCF Growth10 Y	-1.34%
OCF Growth3 Y	-2.73%
OCF Growth5 Y	-10.66%
Revenue Growth	-0.21x
Revenue Growth Q	2.6x
Revenue Growth Quarters	1x
Revenue Growth Years	0x
Revenue Growth3 Y	-6.7x
Revenue Growth5 Y	2.93x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.31
Assets	$201.1B
Cash	$11.7B
Current Assets	$41.4B
Current Liabilities	$32.6B
Debt	$63.5B
Debt EBITDA	$5.88
Debt Equity	$0.74
Debt FCF	$5.78
Equity	$85.5B
Interest Coverage	1.56
Liabilities	$115.6B
Long Term Assets	$159.8B
Long Term Liabilities	$83B
Net Cash	$-51.8B
Net Cash By Market Cap	$-35.2
Net Debt EBITDA	$4.8
Net Debt Equity	$0.61
Net Debt FCF	$4.71
Tangible Book Value	$-33.3B
Tangible Book Value Per Share	$-5.84
WACC	5.06

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	1.27
Inventory Turnover	1.49
Net Working Capital	$-284M
Quick ratio	0.85
Working Capital	$8.7B
Working Capital Turnover	$8.67

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-0.34%
Dividend Growth	0.58%
Dividend Growth Years	15%
Dividend per share	$1.72
Dividend Years	56
Dividend Yield	6.66%
Ex Div Date	2026-07-24
Last Dividend	$0.43
Payout Frequency	Quarterly
Payout Ratio	226.35%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	22.09%
1Y total return	17.38%
200-day SMA	25.85
3Y total return	-10.62%
50-day SMA	25.06
50-day SMA vs 200-day SMA	50under200
5Y total return	-25.59%
All Time High	61.71
All Time High Change	-58.18%
All Time High Date	2021-12-20
All Time Low	0.4
All Time Low Change	6,420.97%
All Time Low Date	1968-03-14
ATR	0.54
Beta	0.28
Beta1y	0.45
Beta2y	0.43
Ch YTD	3.66
High	25.81
High52	28.75
High52 Date	2026-04-02
High52ch	-10.21%
Low	25.3
Low52	23.58
Low52 Date	2025-09-25
Low52ch	9.46%
Ma50ch	3.01%
Premarket Change Percent	0.51
Premarket Price	$25.54
Premarket Volume	739,640
Price vs 200-day SMA	-0.14%
RSI	62.27
RSI Monthly	45.41
RSI Weekly	50.79
Sharpe ratio	0.62x
Sortino ratio	1.24
Total Return	6.32%
Tr YTD	9.01
Tr15y	194.73%
Tr1m	7.98%
Tr1w	2.62%
Tr3m	1.5%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	28
Analyst Count Top	18
Analyst Price Target Top	$29.4
Analyst Ratings	Buy
Analyst Ratings Top	Buy
Earnings EPS Estimate	$0.68
Earnings EPS Estimate Growth	-12.82
Earnings Revenue Estimate	14,425,590,168x
Earnings Revenue Estimate Growth	-1.87x
Operating Income	$18.8B
Operating Income Growth	11.09
Operating Income Growth Q	-0.31
Operating Income Growth3 Y	-10.2
Operating Income Growth5 Y	5.06
Operating margin	29.58
Price target	$28.98
Price Target Change	$12.28
Price Target Change Top	$13.91

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	5,691,606,297%
Float Percent	99.86%
Net Borrowing	1,778,000,000
Shares Insiders	0.03%
Shares Institutions	68.44%
Shares Out	5,699,673,589
Shares Qo Q	-0.56%
Shares Yo Y	0.34%
Short Float	2.88%
Short Ratio	3.21
Short Shares	2.87

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$10B
Adjusted OCF	12,454,000,000
Average Volume	39,392,272.55x
Bv Per Share	14.95
CAPEX	$-2.4B
Ch10y	-26.57
Ch15y	48.68
Ch1m	6.13
Ch1w	2.62
Ch1y	9.69
Ch20y	-0.65
Ch3m	-1.86
Ch3y	-26.3
Ch5y	-42.89
Ch6m	-3.62
Change	1.57%
Change From Open	1.22
Close	25.41
Days Gap	0.35
Depreciation Amortization	6,539,000,000
Dollar Volume	1,215,242,866.5
Earnings Date	2026-08-04
Earnings Time	bmo
EBIT	$4.2B
EBITDA	$10.8B
EPS	$0.76
F Score	7
FCF	$11B
FCF EV Yield	5.52x
FCF Per Share	$1.93
Financing CF	-8,400,000,000
Fiscal Year End	December
Founded	1,849
Goodwill	71,419,000,000
Graham Number	15.98658
Graham Upside	-38.06
Income Tax	$-164M
Investing CF	-5,685,000,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-08-04
Last Report Date	2026-06-28
Last Split Date	1999-07-01
Last Split Type	Forward
Last10k Filing Date	2026-02-26
Lynch Fair Value	$3.8
Lynch Upside	-85.28
Ma150	26.09
Ma150ch	-1.07%
Ma20	24.87
Ma20ch	3.77%
Net CF	-660,000,000
Next Earnings Date	2026-11-03
Open	25.5
Optionable	Yes
P FCF Ratio	13.39
P FCF Ratio SBC	14.66
P OCF Ratio	10.98
P OCF Ratio SBC	11.81
Payment Date	2026-09-01
Position In Range	100
Post Close	25.81
Postmarket Change Percent	-0.19
Postmarket Price	$25.76
Ppne	19,029,000,000
Pre Close	25.41
Price Date	2026-08-05
Price EBITDA	$13.63
Relative Volume	1.2x
Revenue	63,696,000,000x
SBC By Revenue	1.49x
Share Based Comp	947,000,000
Tax By Revenue	-0.26x
Tr20y	153.38%
Tr6m	-0.32%
Us State	New York
Views	1,253
Volume	47,084,187
Z Score	2.22

Frequently asked questions

About this PFE report

What is the latest published PFE stock rating?

Pfizer Inc. is shown with buy in the latest published report, analyzed 2026-05-09. The hub links directly to the full analysis surface where the dated rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full PFE analysis?

The full latest published report, analyzed 2026-05-09, lives at /stocks/PFE/analysis. The bare ticker page summarizes that read and links to each analysis tab; earlier editions remain under /analysis/archive.

What fair-value range is used for PFE?

The latest published report analyzed 2026-05-09 frames PFE around USD 25 to USD 35. This is a dated valuation range, not a live market price; check the valuation, sensitivity, and bear-case tabs before making a decision.

How often is the PFE page updated?

The hub selects the latest published stock report regardless of age and displays its analysis date (2026-05-09). Separately sourced market data is labeled with its own recorded timestamp and is never inferred from the report.

Pfizer Inc. (PFE)

Coverage state: Latest published research available

Generate a fresh PFE analysis

Our latest published analysis: PFE rated Buy

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · PFE

Valuation

Profitability

Balance sheet

Trading

Position sizing & entry playbook

Next earnings

Sector percentile context

All PFE indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on PFE

Frequently asked questions